伏妥昔单抗

化合物

伏妥昔单抗INN:futuximab,开发代号:992 DS),或译夫妥昔单抗福妥昔单抗,是一种嵌合单克隆抗体,设计用于治疗癌症[1]它充当免疫调节剂并与HER1结合。[2][3]

伏妥昔单抗
单克隆抗体
种类完整抗体
目標HER1
臨床資料
其他名稱992 DS
ATC碼
  • 未分配
识别信息
CAS号1310460-85-5
ChemSpider
  • none
UNII
化学信息
化学式C6468H10002N1724O2055S46
摩尔质量146,269.94 g·mol−1

该药物由Symphogen英语Symphogen开发。

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab页面存档备份,存于互联网档案馆), American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-03-06]. (原始内容存档 (PDF)于2016-03-04). 
  3. ^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J. Neurooncol. July 2018, 138 (3): 489–498. PMC 5999169 . PMID 29564747. doi:10.1007/s11060-018-2832-6.